A gluten reduction is the patients’ choice for a dietary ‘bottom up’ approach in IBS—a comment on “a 5Ad dietary protocol for functional bowel disorders” nutrients 2019, 11, 1938 by Shaw, C.C. et al.
This is a repository copy of A gluten reduction is the patients’ choice for a dietary ‘bottom 
up’ approach in IBS—a comment on “a 5Ad dietary protocol for functional bowel disorders”
nutrients 2019, 11, 1938.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/156005/
Version: Published Version
Article:
Shaw, C.C., Buckle, R.L., Rej, A. et al. (3 more authors) (2020) A gluten reduction is the 
patients’ choice for a dietary ‘bottom up’ approach in IBS—a comment on “a 5Ad dietary 
protocol for functional bowel disorders” nutrients 2019, 11, 1938. Nutrients, 12 (1). 137. 
https://doi.org/10.3390/nu12010137
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
nutrients
Comment
A Gluten Reduction Is the Patients’ Choice for a
Dietary ‘Bottom Up’ Approach in IBS—A Comment
on “A 5Ad Dietary Protocol for Functional Bowel
Disorders” Nutrients 2019, 11, 1938
Christian Charles Shaw 1,*, Rachel Louise Buckle 1, Anupam Rej 1 , Nick Trott 1, Imran Aziz 1,2
and David Surendran Sanders 1,2
1 Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS
Foundation Trust, Sheffield S10 2JF, UK; rachel.buckle2@nhs.net (R.L.B.); anupam.rej@nhs.net (A.R.);
nick.trott@nhs.net (N.T.); imran.aziz1@nhs.net (I.A.); david.sanders1@nhs.net (D.S.S.)
2 Academic Unit of Gastroenterology, Department of Infection, Immunity and Cardiovascular Disease,
University of Sheffield, Sheffield S10 2JF, UK
* Correspondence: christian.shaw1@nhs.net
Received: 6 November 2019; Accepted: 20 December 2019; Published: 3 January 2020


Keywords: low FODMAP diet; gluten free diet; irritable bowel syndrome (IBS)
We read the article by Ibrahim and Stribling [1] with interest, as dietary therapies for functional
disorders can be challenging to implement, such as the initial phase of the low fermentable oligo-, di-,
mono- saccharide and polyols (FODMAPs) diet. In view of this, streamlined approaches to achieve
symptom management maybe warranted, such as a ‘bottom up’ approach. Such therapies remove
over-restriction and potentially have fewer concerns regarding nutritional adequacy [2].
The authors voice concerns regarding the effectiveness of dietary therapies for functional bowel
disorders. However, several studies demonstrate the growing evidence for the use of traditional dietary
advice, low FODMAP diet (LFD) and gluten free diet (GFD) for Irritable bowel syndrome (IBS) [3].
We would disagree that the 5Ad protocol is a ‘bottom up’ approach, but rather a ‘top down’
approach, as it involves restriction of high FODMAPs and other dietary components. In contrast, a
GFD could be viewed as a ‘bottom up’ approach, through the reduction of fructans, with a response
rate of 30–71% to this diet [3]. Recent research demonstrated patients use gluten free products, classed
as ‘low fructans foods’, whilst on the LFD personalisation stage [4].
There is limited evidence for the 5Ad protocol and it remains unknown to the public, unlike
the GFD [5]. In addition, the GFD has been rated as more acceptable than the LFD [6]. Only 40%
of individuals have been shown to follow the LFD correctly [7], highlighting the need for easier
approaches such as a gluten restriction.
We further disagree with the authors criticism that the LFD andGFD do not support healthy eating.
The authors refer to the LFD in its entirety as the restriction stage, failing to acknowledge the further
two LFD stages, which aim to ensure nutritional adequacy [8]. O’Keeffe and Colleagues (2018) [4].
demonstrated that nutritional adequacy was not compromised at long-term in the LFD group or in
those returning to a habitual diet 6–18 months follow up.
The nutritional adequacy of the 5Ad remains to be explored, as nutritional analysis was performed
on a ‘model’ diet, shedding no light on how the diet may actually be followed by participants, or if it
was during the intervention.
The 5Ad diet is vague on the reintroduction of foods, providing no food quantity guidance and
concerningly, does not emphasise the importance of food reintroduction. In contrast, a GFD can
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be viewed as less restrictive than the 5Ad diet, as well as the LFD, as there is no requirement for
food reintroduction.
In conclusion, the 5Ad may be viewed as a restrictive dietary approach, with the efficacy and
nutritional adequacy of this diet yet to be determined. Less restrictive options such as a gluten
restriction as a ‘bottom up’ approach to reduce fructans, is biologically feasible, and should be an
option for patients.
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